Medical News

RSS

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

28 Jun 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

Federal Ministry of Health supports radionuclide production at Research Neutron Source

The German Federal Ministry of Health has awarded more than one million euros in research and development funding for the efficient production of an important cancer diagnostic agent at the research neutron source FRM II. In a 2009 feasibility study, the Technische Universitaet Muenchen demonstrated that due to the high neutron flux the neutron source in Garching can produce about half of the European demand of the radioisotope molybdenum-99.

28 Jun 2011

Nine-year-old recovers with experimental heart pump

Nine-year-old Greer Underwood was healthy until February 2011. What seemingly began as sinusitis on a Tuesday became almost fatal by the weekend when her heart began to fail. Now, after a historic series of events at the University of Alabama at Birmingham, she's the only child in the country to have used the experimental heart pump, Heartware, as a bridge to transplant.

28 Jun 2011

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

Palatin Technologies, Inc. announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD).

28 Jun 2011

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.

28 Jun 2011

First Edition: June 28, 2011

Today's headlines include reports from the states about action on public employee benefit reforms and Planned Parenthood funding.

28 Jun 2011

Sentara, TeleHealth Services partner to reduce unplanned re-hospitalizations

TeleHealth Services, the nation's leading provider of healthcare-grade televisions and interactive patient education solutions, today announced a master agreement with Sentara Healthcare as part of the health system's strategy to advance the patient experience and quality of healthcare in its facilities.

28 Jun 2011

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Why is antibody diversity important? Think about it like this, said Myron Goodman, who is an author on the paper: "Why don't you die when I sneeze? It's because you have a powerful immune system. And the way to get a decent immune system is for your body to have a way to respond to insults it has never seen before."

28 Jun 2011

RCSI researchers identify novel drug target for osteomyeltitis

New research from the Royal College of Surgeons in Ireland (RCSI) has identified a novel drug target for the treatment of infection in bone.

28 Jun 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

Merck, UPS extend logistics and distribution agreement

UPS and Merck, known as MSD outside the United States and Canada, today announced that the companies have significantly broadened their existing distribution and logistics agreement to include aspects of Merck's global supply chain around the world.

28 Jun 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

QIAGEN's common shares added to U.S. Russell indexes

QIAGEN N.V. today announced that its common shares were added to the U.S. large-cap Russell 1000 Index and the broad-market Russell 3000 Index.

From QIAGEN Manchester Limited 28 Jun 2011

Drug labels sometimes lack key safety warnings: Consumer Reports Health

It's comparable to driving a car without a seatbelt—a new investigation from Consumer Reports Health finds that drug labels sometimes lack key safety warnings and some pharmacies fail to include the medication guides required by the federal government.

28 Jun 2011

Cynosure announces acquisition of HOYA ConBio's aesthetic laser business

Building on its reputation as a global technology leader in laser and light-based aesthetic systems, Cynosure, Inc. today announced that it has acquired the assets of the aesthetic laser business of HOYA ConBio, a wholly owned subsidiary of Japan-based HOYA Corporation, for $24.5 million in cash. HOYA ConBio is based in Fremont, California.

28 Jun 2011

NEVHC, CHCN select NextGen technology to support Meaningful Use

NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced that Northeast Valley Health Corporation and Community Health Center Network have selected NextGen technology to support their Meaningful Use and business growth initiatives.

28 Jun 2011

MedPro launches pre-filled safety syringe

MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection, today announced the introduction of its pre-filled safety syringe.

28 Jun 2011

Experian to acquire Medical Present Value

Experian, the leading global information services company, today announced that it has signed a definitive agreement to acquire Medical Present Value, Inc., a leading provider of revenue cycle management software, data and analytics to more than 75,000 U.S. physicians.

28 Jun 2011